Overexpression of ubiquitin carboxyl terminal hydrolase-L1 enhances multidrug resistance and invasion/metastasis in breast cancer by activating the MAPK/Erk signaling pathway

Molecular Carcinogenesis

Volumn 55, Issue 9, 2016, Pages 1329-1342

  Wang, Wenjuan ^a   Zou, Liping ^a   Zhou, Danmei ^a   Zhou, Zhongwen ^a   Tang, Feng ^a   Xu, Zude ^a,b   Liu, Xiuping ^b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

breast cancer; invasion; metastasis; multidrug resistance; ubiquitin carboxy terminal hydrolase L1

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CD147 ANTIGEN; DOXORUBICIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; BREAST CANCER; CANCER PROGNOSIS; CANCER RECURRENCE; CELL MIGRATION; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MCF 7 CELL LINE; METASTASIS; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; SURVIVAL TIME; TUMOR INVASION;

EID: 84984984324     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22376     Document Type: Article

References (33)

1. Parrella P. Epigenetic Signatures in Breast Cancer: Clinical Perspective. Breast Care (Basel) 2010; 5:66–73.
2. Su ZZ, Austin VN, Zimmer SG, Fisher PB. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993; 8:1211–1219.
3. Li QQ, Wang WJ, Xu JD, et al. Involvement of CD147 in regulation of multidrug resistance to P-gp substrate drugs and in vitro invasion in breast cancer cells. Cancer Sci 2004; 98:1064–1069.
4. Yamauchi K, Yang M, Hayashi K, et al. Induction of cancer metastasis by cyclophosphamide pretreatment of host mice: An opposite effect of chemotherapy. Cancer Res 2008; 68:516–520.
5. Staroselsky AN, Mahlin T, Savion N, et al. Metastatic potential and multidrug resistance correlation in the B16 melanoma system. J Exp Ther Oncol 1996; 1:251–259.
6. Miletti-González KE, Chen S, Muthukumaran N, et al. The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in Cancer. Cancer Res 2005; 65:6660–6667.
7. Li QQ, Xu JD, Wang WJ, et al. Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells. Clin Cancer Res 2009; 15:2657–2665.
8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385–427.
9. Sharom FJ. ABC multidrug transporters: Structure, function and role in chemoresistance. Pharmacogenomics 2008; 9:105–127.
10. Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is system with an improved hairpin and its significant expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002; 99:520–528.
11. Yang JM, Xu ZD, Wu H, Zhu HG, Wu XH, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res 2003; 1:420–427.
12. Reimers N, Zafrakas K, Assmann V, et al. Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004; 10:3422–3428.
13. Gabison EE, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87:361–368.
14. Li QQ, Wang WJ, Xu JD, et al. Up-regulation of CD147 and matrix metalloproteinase-2, -9 induced by P-glycoprotein substrates in multidrug resistant breast cancer cells. Cancer Sci 2007; 98:1767–1774.
15. Wilkinson KD, Lee KM, Deshpande S, Duerksen-Hughes P, Boss JM, Pohl J. The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 1989; 246:670–673.
16. Case A, Stein RL. Mechanistic studies of ubiquitin Cterminal hydrolase L1. Biochemistry 2006; 45:2443–2452.
17. Li L, Tao Q, Jin H, et al. The tumor suppressor UCHL1 forms a complex with p53/MDM2/ARF to promote p53 signaling and is frequently silenced in nasopharyngeal carcinoma. Clin Cancer Res 2010; 16:2949–2958.
18. Kim HJ, Kim YM, Lim S, et al. Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene 2009; 28:117–127.
19. Caballero OL, Resto V, Patturajan M, et al. Interaction and colocalization of P GP9. 5 with JAB1 and p27Kip1. Oncogene 2002; 21:3003–3010.
20. Lien HC, Wang CC, Lin CH, et al. Differential expression of ubiquitin carboxy-terminal hydrolase L1 in breast carcinoma and its biological significance. Hum Pathol 2013; 44:1838–1848.
21. Miyoshi Y, Nakayama S, Torikoshi Y, et al. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. Cancer Sci 2006; 97:523–529.
22. Schröder C, Milde-Langosch K, Gebauer F, et al. Prognostic relevance of ubiquitin C-terminal hydrolase L1 (UCH-L1) mRNA and protein expression in breast cancer patients. J Cancer Res Clin Oncol 2013; 139:1745–1755.
23. Li QQ, Cao XX, Xu JD, et al. The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci 2009; 66:504–515.
24. Cheng YY, Tao LL, Xu JW, et al. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients. Mol Carcinog 2014; 53:686–697.
25. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT, Jr. The UCH-L1 gene encodes two opposing enzymatic activities that affect α-synuclein degradation and Parkinson's disease susceptibility. Cell 2002; 111:209–218.
26. Osaka H, Wang YL, Takada K, et al. Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 2003; 12:1945–1958.
27. Ma Y, Zhao M, Zhong J, et al. Proteomic profiling of proteins associated with lymph node metastasis in colorectal cancer. J Cell Biochem 2010; 110:1512–1519.
28. Hurst-Kennedy J, Chin LS, Li L. Ubiquitin C-terminal hydrolase L1 in tumorigenesis. Biochem Res Int 2012; 2012: 123706.
29. Akishima-Fukasawa Y, Ino Y, Nakanishi Y, et al. Significance of P GP9. 5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol 2010; 134:71–79.
30. Hussain S, Foreman O, Perkins SL, et al. The de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signaling. Leukemia 2010; 24:1641–1655.
31. Xiang T, Li L, Yin X, et al. The ubiquitin peptidase UCHL1 induces G0/G1 cell cycle arrest and apoptosis through stabilizing p53 and is frequently silenced in breast cancer. PLoS One 2012; 7:29783.
32. Wang WJ, Li QQ, Xu JD, et al. Interaction between CD147 and P-glycoprotein and their regulation by ubiquitination in breast cancer cells. Chemotherapy 2008; 54:291–301.
33. Wang WJ, Li QQ, Xu JD, et al. Over-expression of ubiquitin carboxy terminal hydrolase-L1 induces apoptosis in breast cancer cells. Int J Oncol 2008; 33:1037–1045.